Asperosaponin VI Promotes Osteoporotic Fracture Healing by Targeting Piezo1 to Enhance the Coupling of LEPR BMSCs and PODXL ECs.

Osteoporotic fracture (OPF) has garnered significant attention due to its high incidence of delayed or nonunion, which severely impacts quality of life. However, the pathogenesis remains mysterious, and therapeutic options are limited. The current study aimed to elucidate the molecular pathogenesis of OPF, thereby proposing a novel treatment protocol. In this study, single-cell RNA sequencing analysis was conducted to identify the role of Piezo1 in the osteogenic capacity of LEPR BMSCs in the healing process of fracture. Single-cell trajectory analysis and pseudo-time ordering were used to elucidate the differentiation trajectory of LEPR BMSCs and Piezo1 expression. Molecular docking, cellular thermal shift assay (CETSA), and drug affinity responsive target stability (DARTs) were performed to assess the interaction between Piezo1 and ASP. The ovariectomized (OVX) model combined with femoral bone fracture was utilized to evaluate the osteoprotective effect of ASP in vivo. The alkaline phosphatase (ALP) assay and alizarin red S (ARS) staining were applied to evaluate the osteogenic differentiation potential of LEPR BMSCs. The three-dimensional culture was utilized to assess the proliferation and sphere-forming ability of LEPR BMSCs. The scratch wound healing and tube formation assay were employed to detect the angiogenesis of endothelial cells (ECs). Furthermore, western blotting, immunofluorescence staining, and flow cytometry assays were utilized to detect the relevant protein expression. Initially, single-cell RNA sequencing analysis was utilized to identify Piezo1 as a key factor in osteogenic differentiation of LEPR BMSCs during fracture healing. By molecular docking, CETSA, and DARTs analysis, Asperosaponin VI (ASP) was identified as a potentially effective monomer for Piezo1. Histologically, ASP enhanced the coupling of PODXL ECs and LEPR BMSCs within the callus of osteoporotic fractures. Notably, ASP improved LEPR BMSCs' osteogenic potential and PODXL ECs' angiogenesis. The augmented angiogenic capacity of PODXL ECs was mediated by vascular endothelial growth factor (VEGF), an effect nullified by siPiezo1 in LEPR BMSCs. Further, ASP significantly elevated P-ERK1/2, YAP, and VEGF expression, the downstream molecules of Piezo1 in the LEPR BMSCs.This study initially revealed that the findings suggest that ASP may facilitate the coupling of LEPR BMSCs and PODXL ECs by activating the Piezo1/ERK1/2/YAP/VEGF signaling pathway in LEPR BMSCs, thus indicating a promising therapeutic strategy for osteoporotic fracture management.